Merit Medical Systems: Revenue Model Update and Tariff Benefits Support Buy Rating

Analyst Michael Matson of Needham maintained a Buy rating on Merit Medical Systems (MMSI – Research Report), boosting the price target to $108.00.

Michael Matson’s rating is based on several factors, including the recent updates to Merit Medical Systems’ revenue model. The company has made changes to its revenue categories, particularly by distinguishing between US and international sales. This adjustment provides a clearer picture of the company’s financial performance.
Additionally, Matson has increased the price target for Merit Medical Systems from $100 to $108. This adjustment reflects the positive impact of reduced Chinese tariffs, which is expected to benefit the company’s financial outlook. Despite these changes, the quarterly and annual revenue and EPS estimates remain consistent, supporting the Buy rating.

Matson covers the Healthcare sector, focusing on stocks such as Merit Medical Systems, LivaNova, and TransMedics Group. According to TipRanks, Matson has an average return of -6.9% and a 39.16% success rate on recommended stocks.